DNA and various cellular enzymes

DNA and various cellular enzymes represent a broad and heterogeneous category of pharmacological targets rather than a single molecular entity. DNA serves as the primary repository of genetic information, and drugs targeting it—such as alkylating agents and intercalators—aim to disrupt cellular division, particularly in rapidly proliferating cancer cells (National Cancer Institute, 2023). Cellular enzymes are protein catalysts that regulate virtually all biochemical reactions, including metabolism, signal transduction, and DNA repair (Nature Reviews Drug Discovery, 2018). Because this term encompasses a vast array of distinct molecules, it is typically used in a general context to describe the multi-target profile of certain cytotoxic or broad-spectrum agents. Therapeutic intervention in these areas is foundational to oncology, infectious disease, and chronic inflammatory conditions (StatPearls, 2023). For instance, many antibiotics target bacterial enzymes or DNA to treat infections, while chemotherapy often targets human DNA or enzymes involved in the cell cycle (PubMed, 2022). However, targeting these essential components often carries risks of systemic toxicity due to the essential nature of these components in healthy cells. This category is too broad for specific drug-target validation and usually requires breakdown into specific molecular species for therapeutic development.

Other names

DNA and enzymesGenomic DNA and catalytic proteinsCellular DNA and enzymatic targets

Inhibition of DNA synthesis, induction of DNA damage, and modulation of enzymatic activity through competitive or allosteric inhibition.